These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 24028152)
1. Assessment of cells in the ascitic fluid of women with ovarian hyperstimulation syndrome: the clinical implications for subsequent ovarian malignancy. Hatzipetros I; Gocze PM; Cziraky K; Kovacs K; Kalman E; Farkas B Reprod Biol Endocrinol; 2013 Sep; 11():91. PubMed ID: 24028152 [TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of abdominal fluid cytokine levels in ovarian hyperstimulation syndrome (OHSS). Farkas B; Boldizsar F; Bohonyi N; Farkas N; Marczi S; Kovacs GL; Bodis J; Koppan M J Ovarian Res; 2020 Mar; 13(1):25. PubMed ID: 32138790 [TBL] [Abstract][Full Text] [Related]
3. Dynamic changes of the immunoglobulins in patients with severe ovarian hyperstimulation syndrome: efficacy of a novel treatment using peritoneo-venous shunt. Takamizawa S; Shibahara H; Taneichi A; Obara H; Fujiwara H; Ogawa S; Koike T; Idei S; Sato I Am J Reprod Immunol; 2002 Jan; 47(1):25-30. PubMed ID: 11883746 [TBL] [Abstract][Full Text] [Related]
4. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174 [TBL] [Abstract][Full Text] [Related]
5. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146 [TBL] [Abstract][Full Text] [Related]
6. A severe case of ovarian hyperstimulation syndrome: 65 liters of ascites aspirated in an on-going IVF-ET twin pregnancy. Bar-Hava I; Orvieto R; Dicker D; Dekel A; Peley D; Ben-Rafael Z Gynecol Endocrinol; 1995 Dec; 9(4):295-8. PubMed ID: 8629457 [TBL] [Abstract][Full Text] [Related]
7. [A relation between the polycystic ovary syndrome and the status of ovarian hyperstimulation syndrome in IVF patients after controlled hyperstimulation]. Moosová M; Moos J; Filová V; Pavelková J; Jarosová R; Rezábek K Ceska Gynekol; 2011 Apr; 76(2):123-7. PubMed ID: 21649996 [TBL] [Abstract][Full Text] [Related]
8. Elevated concentrations of angiogenin in serum and ascitic fluid from patients with severe ovarian hyperstimulation syndrome. Aboulghar MA; Mansour RT; Serour GI; Elhelw BA; Shaarawy M Hum Reprod; 1998 Aug; 13(8):2068-71. PubMed ID: 9756270 [TBL] [Abstract][Full Text] [Related]
9. Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome. Aboulghar MA; Mansour RT; Serour GI; El Helw BA; Shaarawy M Eur J Obstet Gynecol Reprod Biol; 1999 Nov; 87(1):81-5. PubMed ID: 10579621 [TBL] [Abstract][Full Text] [Related]
10. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS. Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582 [TBL] [Abstract][Full Text] [Related]
13. Soluble ICAM-1 and E-selectin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome. Abramov Y; Schenker JG; Lewin A; Kafka I; Jaffe H; Barak V Fertil Steril; 2001 Jul; 76(1):51-7. PubMed ID: 11438319 [TBL] [Abstract][Full Text] [Related]
14. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Rizk B; Aboulghar M; Smitz J; Ron-El R Hum Reprod Update; 1997; 3(3):255-66. PubMed ID: 9322101 [TBL] [Abstract][Full Text] [Related]
15. Comparison of follicular fluid and serum levels of Inhibin A and Inhibin B with calculated indices used as predictive markers of Ovarian Hyperstimulation Syndrome in IVF patients. Moos J; Rezabek K; Filova V; Moosova M; Pavelkova J; Peknicova J Reprod Biol Endocrinol; 2009 Aug; 7():86. PubMed ID: 19703287 [TBL] [Abstract][Full Text] [Related]
16. Experience with the bonanno catheter in the management of OHSS from IVF-ET Cycles. Okohue JE; Oriji VK; Ikimalo JI Niger J Clin Pract; 2017 Jul; 20(7):811-815. PubMed ID: 28791974 [TBL] [Abstract][Full Text] [Related]
17. Successful outcome of severe ovarian hyperstimulation syndrome (OHSS) with 27 liters of ascitic fluid removed by paracentesis. Grochowski D; Sola E; Kulikowski M; Kuczyński W; Wołczyński S; Szamatowicz M J Assist Reprod Genet; 1995 Jul; 12(6):394-6. PubMed ID: 8589562 [No Abstract] [Full Text] [Related]
18. Concentration of soluble urokinase plasminogen activator receptor (suPAR) in the pre-ovulatory follicular fluid is associated with development of ovarian hyperstimulation syndrome during ovarian stimulation. Grynnerup AG; Toftager M; Zedeler A; Bogstad JW; Prætorius L; Grøndahl ML; Yding Andersen C; Sørensen S; Pinborg A; Løssl K J Assist Reprod Genet; 2018 Dec; 35(12):2187-2193. PubMed ID: 30232642 [TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Abramov Y; Barak V; Nisman B; Schenker JG Fertil Steril; 1997 Feb; 67(2):261-5. PubMed ID: 9022600 [TBL] [Abstract][Full Text] [Related]
20. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Enskog A; Henriksson M; Unander M; Nilsson L; Brännström M Fertil Steril; 1999 May; 71(5):808-14. PubMed ID: 10231037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]